|
Epidemiology of Candidemia in a Spanish Tertiary Hospital: Identification and Molecular Mechanisms of Resistance (click for details) |
|
|
|
Variability of PKPD of Micafungin (MF) in Critically Ill Patients (CIP) (click for details) |
|
|
|
In vitro Studies of Exserohilum rostratum with Antifungal Drugs and Methylprednisolone (click for details) |
|
|
|
Conventional amphotericin B (AMB) activity against Aspergillus species in an in vitro pharmacokinetic (PK)-pharmacodynamic(PD) model (click for details) |
|
|
|
Impact of Candida species on the Isavuconazole (ISA) Pharmacodynamic (PD) Target in an in vivo Neutropenic Murine Model of Invasive Candidiasis (IC) (click for details) |
|
|
|
Disseminated Histoplasmosis in Costa Rica and the Use of Amphotericin B deoxycholate and Fluconazole as First Line of Theraphy (click for details) |
|
|
|
Safety, Tolerability, and Pharmacokinetics of Posaconazole Oral Suspension in Neutropenic Children (click for details) |
|
|
|
Different Doses of Micafungin for Prophylaxis of Invasive Fungal Diseases: A Web-based Non-Interventional Trial in Four Large University Hospitals in Germany (click for details) |
|
|
|
Caspofungin as Salvage Treatment in Immunocompromised Patients with Pneumocystis Jiroveci Pneumonia (PCP) (click for details) |
|
|
|
Population Pharmacokinetic (PK) Analysis of Voriconazole (VOR) and Anidulafungin (ANID) in Adult Patients wiht Invasive Aspergillosis (IA) (click for details) |
|
|
